Aristoteles Giagounidis

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations

Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes

Luca Malcovati, Ulrich Germing, Andrea Kuendgen et al. · Journal of Clinical Oncology · 2007 · 1K citations

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

Detlef Haase, Ulrich Germing, Julie Schanz et al. · Blood · 2007 · 783 citations · Full text

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Julie Schanz, Heinz Tüchler, Françesc Solé et al. · Journal of Clinical Oncology · 2012 · 683 citations · Full text